GenEditBio
Main focus: Developing safe and effective in vivo gene-editing therapies
Company stage: Pre-clinical
Diseases: Liver diseases and other undisclosed targets
Genome-editing tool: Novel Cas nucleases
Funding stage: Pre-A+
Location: Hong Kong, Hong Kong Island, Hong Kong
Website: GenEditBio
Pipeline: https://www.geneditbio.com/pipeline
Partners:
GenEditBio is a biotechnology company that specialises in gene-editing technologies to develop treatments for diseases that lack effective treatments. The company's goal is to develop a robust gene-editing platform to create safe and efficient therapeutic solutions. GenEditBio primarily focuses on in vivo gene therapies, with future plans to expand into ex vivo gene-edited cell therapies. GenEditBio’s pipeline currently includes five programmes addressing liver tissue and other undisclosed targets.